Moreover, patients with FLT3-ITD AML who receive GO have superior outcomes as compared to patients who do not receive it; this difference is further increased when paired with a consolidative HSCT, such that patients with newly diagnosed FLT3-ITD AML who receive both GO and an HSCT have the best outcomes [140]. The gene discussed is FLT3; the disease is acute myeloid leukemia.